BTIG has reaffirmed its Buy rating and a $30.00 price target for Cullinan Oncology Inc. (NASDAQ: CGEM). The company has recently... ByInvesting.com • Sep 18, 2024 Cullinan Oncology maintains Buy ...

On Thursday, H.C. Wainwright reaffirmed a Buy rating and a $28.00 price target for NASDAQ:CGEM, Cullinan Oncology Inc., following ...

Oncology The Company continues enrollment of disease-specific expansion cohorts of its Phase 1 study. Cullinan remains on track to report initial data for endometrial and cervical cancers in the ...

Dr. Christine Kannler gives free skin cancer screenings at local fire stations across the Commonwealth ...

Zipalertinib (EGFR ex20ins inhibitor), collaboration with Taiho Oncology: EGFR ex20ins NSCLC In January 2025, Cullinan announced that the pivotal Phase 2b portion of REZILIENT1 met the primary ...

Cullinan Therapeutics ... The company is committed to advancing its pipeline in immunology and oncology, with multiple ongoing trials and an emphasis on impactful catalysts for 2025.

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619 ...

On Monday, William Blair initiated coverage on Cullinan Oncology Inc. (NASDAQ:CGEM) stock with an Outperform rating and a fair ...

On Tuesday, Cullinan Oncology Inc. (NASDAQ:CGEM) saw its price target increased to $26.00 from the previous $22.00 by Jones ...